23,837 Shares in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Bought by Algert Global LLC

Algert Global LLC purchased a new stake in shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 23,837 shares of the company’s stock, valued at approximately $74,000.

A number of other institutional investors have also made changes to their positions in TNYA. The Manufacturers Life Insurance Company grew its holdings in Tenaya Therapeutics by 43.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock valued at $72,000 after buying an additional 7,000 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Tenaya Therapeutics by 86.0% in the second quarter. Squarepoint Ops LLC now owns 120,704 shares of the company’s stock worth $374,000 after acquiring an additional 55,816 shares during the last quarter. Integral Health Asset Management LLC increased its position in Tenaya Therapeutics by 3.3% during the second quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock worth $7,208,000 after acquiring an additional 75,000 shares during the period. Renaissance Technologies LLC raised its stake in Tenaya Therapeutics by 144.1% during the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after purchasing an additional 92,960 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Tenaya Therapeutics by 42.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 102,026 shares of the company’s stock valued at $316,000 after purchasing an additional 30,446 shares during the period. 90.54% of the stock is currently owned by institutional investors.

Tenaya Therapeutics Stock Performance

Shares of Tenaya Therapeutics stock opened at $1.77 on Friday. Tenaya Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $7.01. The firm has a market cap of $138.98 million, a P/E ratio of -1.08 and a beta of 2.35. The firm’s 50-day simple moving average is $2.34 and its 200-day simple moving average is $3.41.

Tenaya Therapeutics (NASDAQ:TNYA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.06. On average, equities analysts forecast that Tenaya Therapeutics, Inc. will post -1.52 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Faraz Ali sold 9,748 shares of Tenaya Therapeutics stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.89, for a total transaction of $28,171.72. Following the completion of the transaction, the chief executive officer now directly owns 188,331 shares of the company’s stock, valued at $544,276.59. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 19,539 shares of company stock worth $56,468. Corporate insiders own 32.76% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Monday, July 8th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $15.25.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.